Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Government of Canada

- PMLiVE

US NIH launches mid-stage long COVID trials to evaluate at least four treatments

One trial will test a longer dosing regimen of Pfizer’s antiviral COVID-19 drug Paxlovid

- PMLiVE

Moderna and Merck’s skin cancer vaccine enters late-stage development

More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

- PMLiVE

FDA advisory committee backs updated COVID-19 vaccines targeting XBB variants

The XBB.1.5 variant accounted for nearly 40% of all US COVID-19 cases as of early June

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

- PMLiVE

Novavax announces positive phase 2 results for COVID-19/influenza vaccine candidates

A combination COVID-19/influenza vaccine is included in the mid-stage study

- PMLiVE

WHO declares end to COVID-19 global public health emergency

The agency’s emergency committee said it is time to transition to long-term management of the pandemic

- PMLiVE

WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and RSV

- PMLiVE

Moderna and IBM to explore quantum computing and AI for future mRNA medicines

A growing number of biopharmas have been investing in quantum computing over recent years

- PMLiVE

WHO and global partners launch new effort to address falling childhood vaccination rates

Over 25 million children missed at least one vaccination in 2021 alone

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links